OVERVIEW OF DIRECTIVE 2001/20. Paul Derbyshire. Background & History. Aims of Directive 2001/20
|
|
- Jemima Payne
- 5 years ago
- Views:
Transcription
1 OVERVIEW OF DIRECTIVE 2001/20 Paul Derbyshire Background & History CONDUCT OF TRIALS III/3976/88 (July 1991) ICH/135/95 (January 1997) 2001/20 75/318 Q,S,E Testing Part 4B: GCP 91/507 MEDICINAL PRODUCTS 65/65 Extended Codified 2001/83 75/319 CPMP GMP & PhV 91/356 GMP GCP Directive Conduct of clinical trial: No legal text on application of GCP/GMP No harmonisation between MS 2003/94 GMP 2 Aims of Directive 2001/20 Protect trial subjects Persons incapable of giving legal consent Minors & incapacitated adults Pharmacovigilance procedures monitor ADRs EUDRACT & Eudravigilance databases Improve quality of clinical research Providing a legal basis for GCP/GMP Reduce duplication in paperwork Harmonises ethics committee & competent authority requirements & procedures EUDRACT database Produce credible & reliable data GMP/GCP verification by inspection 3
2 Directive 2001/20 of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use Implementation in 25 Member States will not be Harmonized Must follow National Law & not the Directive 4 Definition Medicinal Product Any substance or combination of substances presented for treating or preventing disease in human beings. Any substance or combination of substances which may be administered to human beings with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in human beings is likewise considered a medicinal product. 5 Definition Clinical Trial Any investigation in human subjects intended to discover or verify the clinical, pharmacological and /or other pharmacodynamic effects of one or more IMP(s), and/or to identify any adverse reactions to one or more IMP(s) and/or to study ADME of one or more IMP(s) with the object of ascertaining its (their) safety and/or efficacy. 6
3 Definition Clinical Trial Includes: All phase I IV trials: Diagnostic, Prophylactic, Therapeutic, Safety, Efficacy, Pharmacokinetic, Pharmacodynamic, Bioequivalence, Dose response, Pharmacogenomic, Pharmacoeconomic etc. Patients or healthy volunteers. Commercial or non-commercial. Excludes Non-Interventional Trials 7 Definition Non-Interventional Trial A study where the medicinal product(s) is (are) prescribed in the usual manner in accordance with the terms of the marketing authorisation. Assignment of the patient to a particular therapeutic strategy is not decided in advance by a trial protocol but falls within the current practice and the prescription of the medicine is clearly separated from the decision to include the patient in the study. No additional diagnostic or monitoring procedures shall be applied to the patients and epidemiological methods shall be used for the analysis of collected data. 8 Non-Interventional Study Use of licensed product within the SmPC Administration not decided by trial protocol Decision to use licensed product is clearly separate from decision to include patient in the trial No additional interventions or tests applied Data collection and analysis epidemiology Collection and analysis of data on a licensed medicinal product used within the approved SmPC during routine clinical practice 9
4 Definition Investigational Medicinal Product A pharmaceutical form of an active substance or placebo being tested or used as a reference in a clinical trial, including products already with a marketing authorisation but used or assembled (formulated or packaged) in a way different from the authorised form, or when used for an unauthorised indication, or when used to gain further information about the authorised form. 10 Investigational Medicinal Product Test substance New active substance Licensed substance used or assembled differently Use of a licensed product for an unauthorised indication Use of a licensed product to gain further information on the product Reference substance: Placebo Active comparator 11 Investigational Medicinal Product Chemical entities Biotechnology products Cell therapy products Gene therapy products Plasma derived products Other extractive products Immunological products (vaccines, allergens, immune sera) Herbal medicinal products Radiopharmaceutical products Homeopathic products 12
5 Article 1- Scope: Applies to commercial & non-commercial trials Article 2 Definitions: New term non-interventional trial Article 3 Protection of subjects Subject/legal representative prior interview before consent Subject contact point? 13 Article 4 Minors Risk threshold & degree of distress defined & constantly monitored Protocol endorsed by EC with paediatric expertise/advice Article 5 Incapacitated adults Life-threatening or debilitating condition Risk threshold & degree of distress defined & constantly monitored Protocol endorsed by EC with relevant expertise/advice Benefit outweighs risk or no risk at all 14 Article 6 Ethics Committee Suitability of supporting staff Investigator payments Strict timelines single request for supplementary information Article 7 Single opinion Single EC opinion per MS 15
6 Article 9 Commencement of a trial Obtain a Clinical Trial Authorisation Implicit authorisation tell & wait Written authorisation Part A products & special characteristics Gene, somatic & xenogenic cell therapy & GMO Timelines amend request once during evaluation 16 Article 10 Conduct of a clinical trial Significant amendments EC opinion 35 days End of trial notification 90 days Early termination or halt 15 days Article 11 Exchange of information European clinical trial database EUDRACT Accessible only to MSs, EMEA & Commission 17 Article 13 Manufacture & Import of IMP Manufacturers/import authorisation Each MS has own timeline & procedure - < 90 days Qualified Person to ensure each batch: Manufactured in compliance with Directive 91/356 (Directive 2003/94) & Annex 13 - GMP Product Specification File & CTA Imported IMP manufactured & checked to equivalent GMP standard, PSF & CTA Imported licensed comparator: Certified manufacture to equivalent GMP or Undergone all relevant analyses, tests or checks to confirm quality in accordance with CTA Maintain a register of certified released batches 18
7 Article 15 Inspection verification Member States to appoint inspectors Results recognised by all Member States Inspection reports available to MSs, EMEA & Ethics Committee. Article 17 Notification of serious adverse reactions SUSARs Fatal or life-threatening 7 days Follow-up within 8 days Other SUSARs 15 days Annual report of all suspected serious ADRs Eurdravigilance clinical trial module database 19 Legal Responsibility Article 2 - Sponsor An individual, company, institution or organisation which takes responsibility for the initiation, management and/or financing of a trial. Article 19 The sponsor or legal representative must be established in the Community 20 Clinical Trial Oversight EUDRACT & Eudravigilance CA Authorisation Monitoring Declaration EC CT Declare date of Commencement Opinion BEFORE Amendments Pharmacovigilance Monitoring DURING End of trial Early termination Temporary halt Declaration AFTER GMP & GCP Inspection Verification 21
8 Areas Covered by 2001/20 Clinical Trial Authorisation Pharmacovigilance Ethics Approval GCP & GMP Inspections GMP of IMP Directive 2003/94 Annex 13 Directive 2001/20 GCP Directive EUDRACT & Eudravigilance Qualified Person Manufacturing & Importation Authorisation 22 Additional Directives & Guidance GCP requirements: New Directive on Principles of GCP 2005? Draft guidance on principles of GCP July 2002 Draft guidance on Trial Master File June 2002 Draft document on Manufacture/Importation Authorisation Holder requirements April 2001 GCP Inspections Draft guidance on qualification of inspectors June 2002 Draft guidance on inspection procedures June Additional Directives & Guidance GMP requirements: Volume 4, Annex 13 July 2003 Directive 2003/94 30 April 2004 Draft document on Manufacture/Import Authorisation application content July 2002 Final guidance documents April 2003 (Notice to Sponsors): EUDRACT database Clinical Trial Authorisation (incl. amendments & end of trial declaration) Ethics Committee Opinion Pharmacovigilance reporting Collection, verification & presentation of AEs/ARs Eudravigilance database 24
9 Major Implications Sponsor or legal representative must be established in the EEA EU manufacture/import sites must have an authorisation All IMPs must comply with GMP & be released by a QP All Phase I IV trials are included CTA required in all EU member states 25 Member States End of easy countries for commencement of clinical studies NL, DE, BE, UK (Phase I healthy volunteer studies) etc. Max. 60 day authorisation procedure with one amendment only Preparation and planning will need to be optimal Protocols will have to be developed to a final concept No back & forward between sponsor & EC One opportunity for response Amendment 35 day procedure Sponsor will need to comply with strict safety reporting timelines Increased level of compliance Monitoring through GCP & GMP inspections & EUDRACT 25 Impact on Clinical Research Organisations Established Pharma: Greater resources & infrastructure to adapt May place early phase studies outside EU Small Medium Sized Pharma: Most affected 10 to 25% increase costs Resources & infrastructure will be lacking QP release Investigator-driven studies less attractive Those dealing with cell or gene therapy products could face delays (180 days) Publicly-Funded Research: Requirement for a single sponsor Vastly increased costs due to additional resources & infrastructure 100 to 400% 26
Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004
Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive
More informationClinical Trials application process, legislation & guidelines
Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission
More informationREQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE:
Annex 1: Clinical trial Application Form REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications AUT-G0001-11 29 MAY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS 3 1
More informationCLINICAL TRIAL AUTHORIZATION APPLICATION FORM
CLINICAL TRIAL AUTHORIZATION APPLICATION FORM Date of Receipt: Date of Triage : Date of valid application: Type of CTC review: NHRA CTA Number: ICTR/ITN Number: Date of Verification of ICTR/ITN: THIS SECTION
More informationANNEX. CHAPTER I General principles
ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I
More informationRegulatory requirements for cell based medicinal products
Regulatory requirements for cell based medicinal products 資料 3-2 Committee 25 August 2010 Dr. Bettina Klug, MSc Paul-Ehrlich-Institut, Langen klube@pei.de Paul-Ehrlich-Institut Federal Institute for Vaccines
More informationTrack III: International Clinical Trials: Global Compliance Norms and EU Focus
Track III: International Clinical Trials: Global Compliance Norms and EU Focus EU Focus Emmanuelle Voisin, PhD Principal, Voisin Consulting May 2008 Rationale Clinical trials in EU important part of health
More informationAgenzia Italiana del Farmaco
Agenzia Italiana del Farmaco The Italian Legislation and the work of the Italian Medicines Agency (AIFA) in the field of ethics of Clinical Trials Umberto Filibeck AIFA Head of GCP Inspectorate and GCP
More informationExplanatory note on general fees payable to the European Medicines Agency
Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, [ ] ENTR/F/2/SF D(2009) [ ] Detailed guidance for the request for authorisation of a clinical trial
More informationClinical Trials Environment EU Legislation: Ausblick auf die neue Gesetzgebung für klinische Prüfungen
The Future of the Regulatory Berlin, 31.05.2013 Clinical Trials Environment EU Legislation: Qualifizierungstag für Study Nurses Ausblick auf die neue Gesetzgebung für klinische Prüfungen Dr. med. Ingrid
More informationChapter 28 Pharmaceutical acquis (human and veterinary medicinal products)
Chapter 28 Pharmaceutical acquis (human and veterinary medicinal products) Screening meeting with Serbia 5 December 2014 DG SANTE D5: Medicinal products - authorisations, EMA; D6: Medicinal products -
More informationSafety Measures in the new Pharmacovigilance System
Safety Measures in the new Pharmacovigilance System Dr. Harald Tietz Director Global Patient Safety & Regulatory Affairs, Germany Lilly Deutschland GmbH Documentation and reporting requirements: Centralisation
More informationSanofi-aventis and Sanofi Pasteur response
Version 18 December 2009 Assessment of the functioning of the «Clinical Trials Directive» 2001/20/EC Public Consultation (ENTR/F/2/SF D(2009) 32674) Sanofi-aventis and Sanofi Pasteur response sanofi-aventis
More informationRegulatory Requirements & Recent Changes, including expectations for APIs & IMPs
Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Neil Raw - GMP Inspector Richard Andrews - Operations Manager 11 th November 2008 Programme: Regulatory Requirements Neil
More informationBelgian Center for Pharamcovigilance for medicines for Human use (BCPH): faggafmps.be
Medicinal Products for Human Use - BELGIUM Competent authority Contact Details Contact Name 1 Federal Agency for Medicines and Health Products (FAMHP) / Agence Fédérale des Médicaments et des Produits
More informationRegulatory and ethics bodies involved in approval process. CA - Submission for authorisation mandatory for
Medicinal Products for Human Use - CZECH REPUBLIC Competent authority Contact Details Contact Name 1 State Institute for Control of Drugs- SÚKL (Státní ústav pro kontrolu léčiv) Phone +420 272 185 111
More informationGMO Technology Conference
GMO Technology Conference The regulation of Clinical Trials on humans involving therapies containing or consisting of genetically modified organisms The Printworks, Dublin Castle 10 th & 11 th October
More informationRSC/CT Det. no. 1/2013
RSC/CT Det. no. 1/2013 Protocol 1631-P The English version of this Determination was prepared in order to help comprehension by non-italian mother tongue users, but is NOT an official document. Please
More informationSubmitting a CTA application to the MHRA
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationImplementation of the EU-law. Tom Van Paepegem Quality co-ordinator D.R.U.G.
Implementation of the EU-law Tom Van Paepegem Quality co-ordinator D.R.U.G. History (1) World War II: Experiments by Nazi-doctors 1946: Nüremberg process 1947: Nüremberg codeddd History (2) 10 basic ethical
More informationDate: 2 nd June 2010 Version: 3 Page 1 of 16 AND LABELLING (NWORTH 3.08) Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10
Page 1 of 16 STANDARD OPERATING PROCEDURE FOR TRIAL SUPPLIES AND LABELLING (NWORTH 3.08) Approvals Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10 Quality Assurance Officer Name: D.
More informationDate: 21 st May 2014 Version: 5 Page 1 of 11. Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May 2014
Date: 21 st May 2014 Version: 5 Page 1 of 11 STANDARD OPERATING PROCEDURE FOR MONITORING CLINICAL TRIALS (NWORTH 3.07) Approvals Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May
More informationINSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience
INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing
More informationDraft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014
20 January 2015 EMA/641479/2014 Compliance and Inspections Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More information378/2007 Coll. ACT of 6 December 2007 on Pharmaceuticals and on Amendments to Some Related Acts (the Act on Pharmaceuticals)
378/2007 Coll. ACT of 6 December 2007 on Pharmaceuticals and on Amendments to Some Related Acts (the Act on Pharmaceuticals) Amendment: 124/2008 Sb. Amendment: 296/2008 Sb. Amendment: 141/2009 Sb. Amendment:
More informationEU Clinical Trial Regulation A view from the Industry
Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty
More informationDevelopment Safety Update Report Guidance
Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationII. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD
II. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD Selected Topics Definitions Communication & Interaction Phase I Clinical Trials Safety
More informationNIMPs (v IMPs): Definitions and Practical Approaches
NIMPs (v IMPs): Definitions and Practical Approaches Esther Sadler-Williams Global Director Strategic Development and Innovation 18 th November 2015 2015 Catalent Pharma Solutions. All rights reserved
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More information-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009
Introduction to Advanced Therapy Medicinal Products Regulation -Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 -Directive 2009/120/EC Dr. Maura O Donovan F.R.C.O.G. MA MD M.R.C.P.I. CAT member
More informationIMP Management and Accountability
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationAgenzia Italiana del Farmaco
Agenzia Italiana del Farmaco European Regulation on Advanced Therapies Cristina Pintus Head of European Relations Unit and Coordinator of the Advanced Therapy Project Italian Medicines Agency Proposal
More informationOverview of Privacy Requirements and Compliance Issues in International Clinical Trials
Overview of Privacy Requirements and Compliance Issues in International Clinical Trials Health Care Compliance Association Research Compliance Conference October 18-20, 2009 Minneapolis, MN 1 Today s Presenters
More informationEuropean Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)
European Academy of Hospital Pharmacy Biotechnology Educational Summit Clinical trials David Gerrett (Acknowledgment Mark Howells) Objectives Have an appreciation and overview of clinical trials Understand
More informationClinical trials from CRA s point of view
Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical
More informationEuropean Medicines Agency Perspective
European Medicines Agency Perspective WMA Workshop on revision of DoH, 4-6 Dec 2012, Capetown, South Africa. Presented by: Fergus Sweeney, PhD Head of Sector, Compliance and Inspection, European Medicines
More informationREQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY:
REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE COMMUNITY For official use: Date of receiving
More informationGUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS
1. PURPOSE This guideline is about the collection, verification, and submission of the reports of adverse events / reactions occurring in clinical drug trials, and code breaking methods. 2. DEFINITIONS
More informationEthics and Clinical trials EU approach
Ethics and Clinical trials EU approach The view I express are my own and do not necessarily reflect those of the European Commission. NO Yes EU Policy In his main speech after his re-election as President
More informationQuality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)
Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations
More informationEMA pharmacovigilance system manual
13 October 2016 EMA/623550/2013 Inspections, Human Medicines Pharmacovigilance & Committees Division Version 1.2 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationSupply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017
Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical
More informationAPI EUROPEAN GMP REQUIREMENTS. Alessio Ferrari
API EUROPEAN GMP REQUIREMENTS Alessio Ferrari SUMMARY GUIDELINES IMPLICATIONS FOR THE INDUSTRY ARTICLE 46 (F) OF DIRECTIVE 2001/83/EC PART I EU GMP Chapter 5 OFFICIAL MEASURES TO PROTECT. PROCEDURE TO
More informationEUROPEAN UNION. Brussels, 4 April 2014 (OR. en) 2012/0192 (COD) PE-CONS 2/14 PHARM 5 SAN 9 MI 11 COMPET 12 CODEC 25
EUROPEAN UNION THE EUROPEAN PARLIAMT THE COUNCIL Brussels, 4 April 2014 (OR. en) 2012/0192 (COD) PE-CONS 2/14 PHARM 5 SAN 9 MI 11 COMPET 12 CODEC 25 LEGISLATIVE ACTS AND OTHER INSTRUMTS Subject: REGULATION
More informationOFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies
OFFICE FOR RESEACH PROCEDURE Sponsor Responsibilities in Investigator Initiated Studies 1. Purpose: To define Sponsor Responsibilities in the conduct of Investigator driven studies. 2. Scope: All phases
More informationCentral Committee for Research Involving Human Subjects/ Centrale Commissie Mensgebonden Onderzoek (CCMO) NB! if CCMO acts as CA:
Medicinal Products for Human Use - NETHERLANDS Competent authority Contact Details Contact Name 1 Central Committee for Research Involving Human Subjects/ Centrale Commissie Mensgebonden Onderzoek (CCMO)
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationVOLUME 9 - PHARMACOVIGILANCE. Medicinal Products for Human and Veterinary Use
VOLUME 9 - PHARMACOVIGILANCE Medicinal Products for Human and Veterinary Use FOREWORD Directive 75/319/EEC as amended by Commission Directive 2000/38/EC of 5 th June 2000 and Directive 81/851/EEC as amended
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationThe Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective
The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective Almath Spooner, Irish Medicines Board Pharmaceutical Society of Ireland National Pharmacy Summit, November 2008. Presentation Topics
More informationAdvanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4. Relevant Financial Relationships - None
EAHP March 2016 Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4 Dr. Lenka Taylor Pharmacy University Hospital Heidelberg Disclosure Relevant Financial Relationships
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and
More informationGood Clinical Practice (GCP) & Clinical Trial Registries
Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,
More informationClinical Trial Safety Reporting requirements
Clinical Trial Safety Reporting requirements SME info day 20 Mar 2017 Presented by Sophia Mylona Clinical & Non-clinical Compliance, European Medicines Agency An agency of the European Union Article Regulation
More informationAnnual report 2011 Clinical trials of medicines in humans
Annual report 2011 Clinical trials of medicines in humans 1 Highlights Below is a summary of some of the topics covered by the Danish Health and Medicines Authority's annual report on clinical trials of
More informationImplementing the Directive - from the Swedish Perspective. Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials
Implementing the Directive - from the Swedish Perspective Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials Previous system in Sweden CA (LVFS 1996:17) Approval of applications
More informationarena that impact on clinical development
RESEARCH DEVELOPMENT Changes in the regulatory arena that impact on clinical development 23 May 2011 Agenda Voluntary Harmonisation Procedure PIP and Paediatric requirements Changes to EudraCT and European
More informationEU Perspective on Regulatory Issues for Biologics
Oncology Biologics Development Primer 29 February 2008 Robert Charnas Disclosure Employee and shareholder of Amgen, Inc. Thousand Oaks, CA Worked in Basel, Switzerland for 19 Years and dealt with European
More informationGuideline on the processing of renewals in the centralised procedure
22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation
More informationPharmacovigilance System Master file
IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC AND REGULATION (EC) NO 726/2004 Pharmacovigilance System Master file
More informationWorkstream 6: Pharmacovigilance
Workstream 6: Pharmacovigilance 1.0 Introduction... 2 1.1 Background... 2 1.2 Definitions... 3 2.0 Definition of Sponsor for Pharmacovigilance... 4 3.0 General Considerations: Risk Adapted Approaches to
More informationGUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.2 December 2008 GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationImplementing the New Pharmacovigilance Legislation
Implementing the New Pharmacovigilance Legislation Irish Medicines Board, Pharmacovigilance Information Day, Dec 2011 Dr. Almath Spooner Vigilance Assessment Manager, Human Products Monitoring Department
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/876333/2011 Rev 4* Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 4) Date for coming into effect of first version 2 July 2012 Date for coming into effect
More informationVOLUME 4 Good manufacturing practices ANNEX 13 Manufacture of investigational medicinal products JULY 2003
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, F2/BL D(2003) Revision
More informationSTANDARD OPERATING PROCEDURE
Research and Development STANDARD OPERATING PROCEDURE PHARMACOVIGILANCE S22 Post holder responsible for SOP: Anoushka Tepielow Position: Assistant R&D Manager Author: Anoushka Tepielow Position: Assistant
More informationDoc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021
National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda Tel: 256-0414 - 255665/347391/2 E-mail: ndaug@nda.or.ug Website: http://www.nda.or.ug Doc. No. DPS/GDL/034
More informationNew Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012
New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE
More informationE2B, Safety databases & Eudravigilance
E2B, Safety databases & Eudravigilance Delphine BERTRAM, PharmD Hospices Civils de Lyon France HOT TOPICS IN PV Hod Hasharon 7 May 2014 Dr Irene Fermont- ISOP ISRAEL Dganit Even Sapir -MSD Spontaneous
More informationMANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS
ANNEX 13 MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS Introduction Medicinal products intended for research and development trials are not at present subject either to marketing or manufacturing Community
More informationRe: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance
07 November 2011 By email: sanco pharmaceuticals@ec.europa.eu Directorate General for Health and Consumers Unit SANCO/D/3 BE 1049 Brussels Belgium Dear Sirs, Re: PCIM/11/01 Public Consultation on Implementing
More informationClinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski
Clinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski Agenda Why are clinical trials conducted? History Guidelines and Regulations When are trials conducted? Requirements
More informationInspections: an academic perspective
Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk
More informationInvestigational Medicinal Product (IMP) Management Standard Operating Procedure
Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support
More informationIntroduction to clinical trials Magnus Kjaer
Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions
More informationEMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9).
EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9). Responsible, under the Head of Unit for the Post-Authorisation Evaluation of Medicinal Products
More informationThe rules governing medicinal products in the European Union. Presentation and content of the dossier Edition
The rules governing medicinal products in the European Union Volume 2B Notice to Applicants Medicinal products for human use Presentation and content of the dossier 1998 Edition EUROPEAN COMMISSION Directorate
More informationA GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Pharmaceuticals and cosmetics Final Revision 0 NOTICE TO APPLICANTS A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 This guideline
More informationAuthor Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document
SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing
More informationFormat and content of electronic periodic safety update reports (Technical contribution to EC implementing measure)
Format and content of electronic periodic safety update reports (Technical contribution to EC implementing measure) First Stakeholders Forum on the implementation of the new Pharmacovigilance legislation,
More informationData Collection Tools Functions, Indicators & Sub-Indicators
Data Collection Tools 27- Functions, Indicators & A. National regulatory system Indicator RS1: Legal framework for establishment of a regulatory system, mandate and enforcement power for each function
More informationRoles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)
Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of
More informationMedical Devices. LITHUANIA LAWIN Lideika, Petrauskas, Valiunas ir partneriai
Medical Devices LITHUANIA LAWIN Lideika, Petrauskas, Valiunas ir partneriai CONTACT INFORMATION Ruta Pumputiene LAWIN Lideika, Petrauskas, Valiunas ir partneriai Jogailos str. 9 / 1, LT-01116 Vilnius,
More informationFergus Sweeney, European Medicines Agency
Fergus Sweeney, European Medicines Agency Disclaimer The views presented in this presentation/these slides are those of the author and should not be understood or quoted as being made on behalf of the
More informationEphMRA Adverse Event Reporting Guidelines 2016
EphMRA Adverse Event Reporting Guidelines 2016 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
More informationEuropean Commission: Assessment Of The Functioning Of The Clinical Trials Directive 2001/20/EC. MRC Response to Public consultation on EUCTD
European Commission: Assessment Of The Functioning Of The Clinical Trials Directive 2001/20/EC MRC Response to Public consultation on EUCTD January 8 th 2010 Introduction The Medical Research Council (MRC)
More informationMedicinal Products for Human Use. September 2015
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health Systems and products Brussels, (2015) Revision 12 NOTICE TO APPLICANTS Medicinal Products for Human Use VOLUME 2B Module 1.2: Administrative
More informationClinical Research Service Provider Information Form
Clinical Research Service Provider Information Form General information Name of Organisation Real Regulatory Limited Contact information Head of Organisation: Main contact Name: Derval OCarroll Address:
More information